Your business drives us.
Results define us.

The Commodity Futures Trading Commission (the CFTC or Commission) issued a notice of proposed rulemaking on June 10, 2026, seeking public comment on proposed amendments to CFTC Regulation 40.11. The proposed amendments further specify the types of event contracts that may be subject to a public interest determination under Section 5c(c)(5)(C) of the Commodity Exchange Act (CEA), i.e., the "Special Rule" that authorizes the CFTC to prohibit the trading or clearing of certain event contracts on or through CFTC-registered entities.

Katten announced today that Kimberly Smith, partner and global chair of the firm's Corporate department, has been selected to the inaugural Forbes America's Top Women Lawyers list for 2026. The list and accompanying feature story spotlight a rarefied group of elite attorneys in private practice and is based on a rigorous, multi-stage process of editorial research and analysis designed to identify the finest in the profession.

The prediction markets industry reached a significant milestone. The US Commodity Futures Trading Commission (CFTC) announced the adoption of a Notice of Proposed Rulemaking (NPRM) that proposes a clearer regulatory framework for event contracts and signals the agency’s continued focus on a sector that has experienced rapid growth and increased public attention.

The private credit market is navigating a complex environment, one in which artificial intelligence (AI) is emerging as a potentially transformative force in how private credit transactions are sourced, evaluated, documented and managed throughout the investment lifecycle. The increased focus on AI coincides with continued growth across the private credit industry. AI adoption across the private credit landscape is raising important legal, regulatory, and risk-management considerations for lenders, sponsors and borrowers alike.

Katten represented Mylan Pharmaceuticals Inc. in winning a judgment against Actelion Pharmaceuticals Ltd. in significant patent litigation over its epoprostenol formulation patents.

In a precedential decision issued on May 13, the US Court of Appeals for the Federal Circuit affirmed the Northern District of West Virginia's ruling that Mylan's proposed generic epoprostenol product doesn’t infringe Actelion's asserted patents relating to formulations of epoprostenol, the active ingredient in Actelion's Veletri® product. The decision, Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc., No. 2024-1641, caps a second successful win at the Federal Circuit for Mylan, following the court's 2023 decision vacating an earlier judgment and remanding for further consideration of extrinsic evidence.